Increasing unusual option volume: INSM CRDO FFIE GTHX CIM BNED CAMT

Go back to Increasing unusual option volume: INSM CRDO FFIE GTHX CIM BNED CAMT

Insmed (INSM) PT Raised to $67 at Stifel

May 30, 2024 4:35 PM EDT

Stifel analyst Stephen D. Willey raised the price target on Insmed (NASDAQ: INSM) to $67.00 (from $39.00) while maintaining a Buy rating.

The analyst comments "We believe topline P3 ASPEN results will establish brensocatib as the first-approved, standardof-care therapy in NCFBE and meaningfully improve investor... More

Insmed (INSM) PT Raised to $58 at UBS

May 29, 2024 5:37 AM EDT

UBS analyst Trung Huynh raised the price target on Insmed (NASDAQ: INSM) to $58.00 (from $46.00) while maintaining a Buy rating.

The analyst comments "Management believes from now through the regulatory review process, the path is noncontroversial given the strength of data presented... More